The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Clarke
Marilyn L
ML
Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Mackey
John R
JR
Baldwin
Stephen A
SA
Young
James D
JD
Cass
Carol E
CE
D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001692:Biological Transport; D000069287:Capecitabine; D002462:Cell Membrane / Q000378:metabolism*; D017338:Cladribine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D014407:Tumor Cells, Cultured; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D003841:Deoxycytidine; D017338:Cladribine; D000069287:Capecitabine; D014740:Vidarabine; C024352:fludarabine; D005472:Fluorouracil; D000093542:Gemcitabine